Ampakine stimulant drug. Memory improvement, Cognitive enhancement, Stimulation, Reversing cognitive deficits.
IDRA-21 is a nootropic that has been introduced to the market fairly recently. It acts as an ampakine stimulant drug and studies are currently being undertaken to further research its effects into memory improvement, cognitive enhancement, stimulation, and reversing cognitive deficits.
Ampakine stimulants are allosteric modulators of AMPA receptors in the brain. These AMPA receptors are in charge of fast synaptic transmission and are involved in synaptic plasticity and long term potentiation.
Being an ampakine the IDRA-21 works through the modulation of AMPA receptors in the brain. It is responsible for binding the allosteric site and subsequently forcing positive modulation. Some refer to this process as allosteric activation.
To date, studies have focused almost exclusively on determining its potential for the treatment of a series of conditions of neurological nature such as Alzheimer's disease, Parkinson's disease, and the cognitive deterioration that stems from the aging process.
Animal-based tests have proven that IDRA-21 gives users cognitive enhancement that is long-lasting. This manifests itself in improved memory and learning skills after just one dose.
To date, there have been no human clinical trials of the IDRA-21; however, a few nootropic users were able to try out the compound and reported a series of cognitive enhancements from using the compound. The reported benefits were: a heightened sensory perception, higher motivation, and sustained mental focus that lasted the whole day. In addition to the benefits in focus and sensory perception, some users also commented on positive effects on anxiety and depression.
It is worth noting however that those who tried IDRA-21 experienced side effects that are commonly associated with the use of nootropics and ampakines. These side effects include: headaches, mood swings, dizziness, anxiety, insomnia, nausea, sweating, and restlessness.